Open Medicine Institute Overview

OMI—founded in 2009 by Dr. Andreas Kogelnik—is thinking outside the box to apply a multi-disciplinary, “big data” approach to advance the understanding of “difficult” diseases and improve patient outcomes. To do this, we are merging recognized clinical expertise with sophisticated bio and computer technologies to unify healthcare information from many sources and make it available where it is needed. OMI was founded on the principles of the open source movement, which calls for systems and information to be shared in a community-based, collaborative manner. The combination of community and technology is the driving force behind our new approach to medicine.

OMI maintains a clinical research facility based in Mountain View, CA, including clinical space, a laboratory draw station and core biotechnology/immunology research laboratory, informatics core, and physiology laboratory.  In addition, OMI interacts with a large network of like-minded international collaborators — patients, independent physicians, academic centers, informatics groups, laboratories, industry, large health systems, and others.

A Novel Technology Platform

OMI has developed and is employing a novel technology platform—OpenMedNet—that facilitates information sharing (patient consented and HIPAA compliant) from all sources (patient, caregiver, physician, hospital, lab, etc.) and optimizes collaboration.

A Focus on Neuro-Immune Diseases and Cancer

The Institute is currently focused on understanding, developing treatments, and finding cures for neuro-immune diseases including ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome), Autism, Multiple Sclerosis, and other conditions. There are also plans to apply the Institute’s model to a range of diseases including cancer and Alzheimer’s—diseases which have proved difficult, if not impossible, to decode and treat using today’s standard approaches.

A Community-Based Initiative

OMI is a community-based organization, providing benefits directly to patients, supporting community physicians and hospitals, and contributing to the understanding of disease and treatments. The Institute is a California community benefits corporation (“B corp”)—defined by its focus on delivering value to the community ahead of profits to its shareholders.

OMI has received funding from the CDC to advance research into ME/CFS, and is crowd-sourcing private funds to support diagnostic and treatment trials in the US and internationally. If you believe in the work we’re doing, please consider making a donation.